ADHC .0029 Took some on this news...
American Diversified Holdings Corporation ("ADHC"-PK) Formally enters $200 Billion Cannabis Industry by forming Operating Business: American Cannabis Holdings, Inc.
Press Release | 10/16/2018
ADHC Files Current Year End Financials Valuing AURACISTM Migraine Bio-Device Patents In Excess of $500,000
DEL MAR, CA / ACCESSWIRE / October 16, 2018 / American Diversified Holdings Corporation (OTC PINK: ADHC) has filed its current year end financials which can be found under the ticker symbol ADHC at www.otcmarkets.com
After closely following the Cannabis markets ADHC management has determined the timing is appropriate for entering this sector and has formed an operating business which will be the vehicle for managing business initiatives. The company will be offering a selection of life style products in the legal cannabis market as our first initiatives in the Cannabis sector.
The impetus to fully enter the Cannabis space is based upon several events have occurred; including full legalization in Canada on October 17th, Relaxation of federal rules on CBD, Major investments by multi-national beverage companies in the infused beverage arena and numerous analyst reports indicating the US Cannabis market to grow to over $200 billion in the next decade.
American Cannabis Holdings Inc. will be initially focused on Direct to Consumer markets primarilyin infused beverages, Medical Cannabis and will continue to monitor the US federal policy for additional market opportunities.
Management is in late stage negotiations with Cannabis industry partners and will be updating shareholders in the near term.
In additional news ADHC has filed its' current year end financials. Brazos Biomedical, Inc. and its patented technology AURACISTM migraine management device are progressing along its development path.
"The Auracis international patent portfolio includes two issued US patents and international counterparts. The patent portfolio covers the head-worn, electrode-containing device to be used for pain from migraine headaches," commented ADHC management.
ADHC recently filed financials value the patent portfolio in excess of $500,000. Recent reports indicate that the US migraine surpasses $55 billion in treating over 38 million people suffering from migraines.
The AURACISTM TENS (transcutaneous electric nerve stimulation) migraine device was derived from the OMEGA surgical procedure, where electrodes are implanted in the cranium under the skin blocking nerve impulses. Management believes a less invasive non-surgical non-opioid head worn TENS device will provide relief for the millions of patients that do not qualify for a surgical procedure or are looking for an alternative to traditional medications.
Investors can find a complete overview of all the AURACIS information on the www.BrazosBiomedical.com website.
ADHC is a holding company that provides executive management, corporate governance, administrative support, financial advice, and introductions to capital sources to various micro-cap private and public companies that have proven revenues and business models.
BRAZOS BIOMEDICAL LLC is a bio device company utilizing electro stimulation for pain management to improve patient outcomes through creative innovation with a core competency in the migraine and headache pain space.
DD makes the charts, the charts don't make the DD.
